✦ LIBER ✦

Erratum: Activity and Tolerability of Nilotinib: A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant

✍ Scribed by Maya Koren-Michowitz; Philipp le Coutre; Justus Duyster; Christof Scheid; Panayiotis Panayiotidis; Witold Prejzner; Jacob M. Rowe; Michaela Schwarz; Neta Goldschmidt; Arnon Nagler

Book ID: 102111778
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 41 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25569

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity and tolerability of nilotinib :

Activity and tolerability of nilotinib : A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant

✍ Maya Koren-Michowitz; Philipp le Coutre; Justus Duyster; Christof Scheid; Panayi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

## Abstract ## BACKGROUND: Nilotinib is active in imatinib‐resistant and ‐intolerant chronic myeloid leukemia patients and was recently approved for these indications. ## METHODS: Data on the efficacy and safety of nilotinib treatment were collected from 2 phase 2 expanded access clinical trials

A retrospective analysis of therapy adhe

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting

✍ Guérin, Annie; Chen, Lei; Wu, Eric Q.; Ponce de Leon, Diego; Griffin, James D. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 174 KB

Nilotinib in imatinib-resistant or imati

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

✍ Giles, F J; le Coutre, P D; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottman 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 383 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH

Lack of non-hematological cross intolera

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

✍ Yukio Kobayashi; Hisashi Sakamaki; Shin Fujisawa; Kiyoshi Ando; Kazuhito Yamamot 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 152 KB

Dasatinib, even at low doses, is an effe

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

✍ Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB